<DOC>
	<DOCNO>NCT00498407</DOCNO>
	<brief_summary>Patients histologically cytologically confirm metastatic colorectal cancer ( CRC ) fail first-line chemotherapeutic regimen contain oxaliplatin 5-fluorouracil ( 5-FU ) without bevacizumab , without Investigational Medicinal Products ( IMPs ) , receive CP-4055 200 mg/m2/day intravenously ( IV ) Day 1-5 every four week complete response disease worsening/progressing .</brief_summary>
	<brief_title>A Phase II Study CP-4055 Second Line Therapy Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>This multicentre clinical study conduct United Kingdom . It open label study design investigate objective response rate ( RR ) , time progression ( TTP ) duration tumor response patient colorectal cancer treat CP-4055 . The quantitative qualitative toxicity treatment also assess .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm metastatic CRC fail firstline chemotherapeutic regimen contain oxaliplatin 5fluorouracil ( 5FU ) without bevacizumab , without Investigational Medicinal Products ( IMPs ) 2 . Measurable disease accord Response Criteria In Solid Tumours ( RECIST ) 3 . Performance Status 0 2 accord ECOG ( Eastern Cooperative Oncology Group ) Performance Status 4 . Age 18 year 5 . Life expectancy &gt; 3 month 6 . Signed informed consent ( IC ) 7 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must negative serum urine pregnancy test within 2 week prior CP4055 treatment . Nursing patient exclude . 8 . Male female patient must use acceptable contraceptive method duration time study , male also 3 month last CP4055 dose 9 . Adequate haematological biological function 1 . Known brain metastasis 2 . Radiotherapy 30 % bone marrow 3 . Participation another therapeutic clinical study within 30 day enrolment clinical study 4 . Concomitant treatment nonpermitted medication : Alternative drug High dos vitamins 5 . History allergic reaction araC egg 6 . Any serious concomitant systemic disorder incompatible clinical study ( e.g . uncontrolled intercurrent illness include ongoing active infection ) 7 . Any significant central nervous system psychiatric disorder ( ) would hamper patient 's compliance 8 . Pregnancy , breastfeed absence adequate contraception male female fertile patient 9 . Known positive status HIV and/or hepatitis B C 10 . Drug and/or alcohol abuse 11 . Any reason , investigator 's opinion , patient participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>CP-4055</keyword>
	<keyword>ELACYT ( TM )</keyword>
	<keyword>Cancer</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>CRC</keyword>
	<keyword>Second line therapy</keyword>
</DOC>